Open menu

Nanotechnology General News

The latest news from academia, regulators
research labs and other things of interest

Posted: November 12, 2008

New Nanoparticle Drug Delivery Report Available

(Nanowerk News) Research and Markets has announced the addition of the "Nanoparticle Drug Delivery" report to their offering.
Advances in nanotechnology that enable drugs to be delivered in ways that preserve their efficacy and to precise therapeutic targets are creating a host of opportunities for drug developers. A variety of nanostructures are being investigated as functional drug carriers for a wide range of therapies, most notably cardiovascular medicine, autoimmune diseases, and cancer. While the concept of nanoparticles in drug delivery is not new, the number of research programs and active drug development projects has escalated as funding to nanotechnology developers has increased. The result is the emergence of a host of novel nanotechnologies tailored to meet the physicochemical requirements of drug developers. Nanoparticles have already improved the availability and efficacy of some drugs, and the capabilities that evolving technologies possess will leads to a dramatic increase in the number of therapies delivered via nanoparticles
The study presents qualitative and quantitative data and information on key demand factors and trends:
  • Nanoparticle Technology Competitive Assessment
  • Nanoparticle Drug Development Factors
  • Near-Term Nano-Drug Disease Therapies
  • Nanoparticle Technology Commercialization Issues
  • Technology-driven Performance Factors
  • Opportunity Assessment and Factors Limiting Growth
  • Drug Design and Development Factors
  • Sector Participant Profiles
  • For more information visit
    Source: Research and Markets (press release)
    Subscribe to a free copy of one of our daily
    Nanowerk Newsletter Email Digests
    with a compilation of all of the day's news.
    If you liked this article, please give it a quick review on reddit or StumbleUpon. Thanks!
    These articles might interest you as well: